Moclobemide
- Atc Codes:N06AG02
- CAS Codes:71320-77-9
- PHARMGKB ID:71320-77-9
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Aurorix, Moclobemid; Belgium: Aurorix, Moclobemide; Bulgaria: Aurorix, Moclobemide; Czech Republic: Apo-Moclob, Aurorix; Denmark: Aurorix, Moclobemid, Moclostad; Finland: Aurorix, Moclobemid; France: Moclamine; Germany: Aurorix, Deprenorm, Moclobemid, Moclobeta, Moclodura, Rimoc; Greece: Aurorix; Hungary: Aurorix, Maorex, Mocrim; Ireland: Manerix; Luxembourg: Aurorix, Moclix; Malta: Manerix, Moclobemide; Netherlands: Aurorix, Moclobemide; Poland: Aurorix, Mobemid, Moclobemid, Mocloxil, Moklar; Portugal: Aurorix, Moclobemide, Zorix; Slovakia: Aurorix, Moclobemid; Slovenia: Aurorix; Spain: Manerix, Moclobemida; Sweden: Aurorix, Moclobemid; UK: Manerix, Moclobemide.
North America
Canada: Manerix, Moclobemide.
Latin America
Brazil: Aurorix; Mexico: Aurorex, Demobal.
Drug combinations
Chemistry
Moclobemide: C~13~H~17~ClN~2~O~2~. Mw: 268.74. (1) Benzamide, 4-chloro-N-[2-(4-morpholinyl)ethyl]-; (2) p-Chloro-N-(2-morpholinoethyl)benzamide. CAS-71320-77-9 (1987).
Pharmacologic Category
Antidepressants; Monoamine Oxidase Inhibitors, Reversible. (ATC-Code: N06AG02).
Mechanism of action
Inhibits metabolism (deamination) of serotonin, norepinephrine, and dopamine, leading to increased concentrations of these neurotransmitters; this may account for antidepressant activity of drug.
Therapeutic use
Symptomatic relief of depressive illness.
Pregnancy and lactiation implications
Safety not established, use only if benefits outweigh risks. Enters breast milk (use caution during lactation).
Unlabeled use
Contraindications
Hypersensitivity to moclobemide or any component of the formulation. Uncontrolled hypertension. Hepatic disease. Confusional states. Concurrent use of sympathomimetics (and related compounds), MAOIs, meperidine, tricyclic antidepressants, serotonergic drugs (including SSRIs). General anesthesia, local vasoconstrictors. Spinal anesthesia (hypotension may be exaggerated). Patients under 18 years of age.
Warnings and precautions
Suicidal thinking/behavior possible. Use with caution in hepatic impairment, pheochromocytoma, renal impairment, thyrotoxicosis, and in patients receiving concurrent buspirone. Effects may be potentiated when used with other sedative drugs or ethanol. Severe reactions may occur if MAOIs and serotonergic agents (including SSRIs) are used concurrently.